Breaking News

Impax Laboratories Names CFO

December 13, 2012

Reasons takes over interim role

Bryan M. Reasons has been appointed senior vice president and chief financial officer at Impax Laboratories. Mr. Reasons joined the company in January 2012 as vice president of finance and has served as acting CFO since June 2012.
Prior to joining the company, Mr. Reasons served as vice president of finance, as well as vice president of risk management and general auditor, at Cephalon, Inc. Following the acquisition of Cephalon by Teva, he served briefly as the vice president of finance at Teva.
“Following a nationwide search, Bryan Reasons was selected as the best candidate to fill the CFO role,” said Larry Hsu, Ph.D., president and chief executive officer, Impax Laboratories. “He has a breadth of knowledge across accounting and finance, combined with extensive merger and acquisition experience within the pharmaceutical industry. In less than two years, we have significantly transformed Impax’s leadership team across a number of functions as we focus on executing our growth strategy.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks